Magellan Rx Management, LLC earns URAC Accreditation in Health Utilization Management

Designation demonstrates highest level of commitment to quality health care

February 8, 2024

EAGAN, Minn. – Feb. 8, 2024 – Prime Therapeutics LLC (Prime) is proud to announce that Magellan Rx Management, LLC (MRx) has earned URAC accreditation for Health Utilization Management (HUM). URAC is the independent leader in promoting health care quality by setting high standards for clinical practice, consumer protections, performance measurement, operations infrastructure and risk management. By achieving this status, MRx demonstrates commitment to quality care, enhanced processes, patient safety and improved outcomes.

“It’s gratifying to be endorsed for serving our patients with clinically sound programs that improve the quality and effectiveness of their care while eliminating unnecessary treatment and expense,” said Matthew Mertel, chief operating officer for Prime. “The URAC HUM Accreditation is validation that we’re delivering on our promise to provide the health care experience we want for our loved ones, while ensuring they receive effective and efficient care.”

URAC HUM is an industry standard that indicates MRx performs its utilization management (UM) functions in an effective, transparent and efficient manner. UM is presently seen as a valuable tool to ensure accessibility, quality and timeliness of care. Consequently, URAC keeps pace with the changing health care industry by defining best practices grounded by the real experiences of valued clients and industry experts.

“URAC accreditation shows that MRx adheres to best-in-class industry standards for clinical excellence, collaborative care, patient empowerment, risk management and organizational leadership and accountability. With this distinction, MRx demonstrates excellence in quality health care delivery and their commitment to ensuring patient safety,” said URAC President and CEO Shawn Griffin, M.D.

Related news

Press releases

April 11, 2024

Prime Therapeutics and Magellan Rx to present eight managed care pharmacy research studies at AMCP

Prime/MRx remains at the forefront of GLP-1 research, presenting weight loss studies at this year’s annual meeting

Press releases

March 13, 2024

Prime Therapeutics and Capital Rx Enter Into Transformative Strategic Alliance

Strategic alliance allows Prime to offer exclusive access to Capital Rx’s leading technology platform to achieve a higher standard of care, increase efficiency, improve experiences and provide the foundation for the next generation of integrated pharmacy care for the more than 50 million Americans served by Prime

Press releases

December 5, 2023

Prime Therapeutics announces Ken Bodmer as chief financial officer

EAGAN, Minn. – Today, Prime Therapeutics LLC/Magellan Rx Management LLC (Prime/MRx) announces that…